Instrument Inactif

Communiqués LENZ Therapeutics, Inc. OTC Markets

Actions

GRPH

US52635N1037

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 17:42:55 11/09/2026			Varia. 5j.	Varia. 1 janv.
4,595 ^USD	-79,36%		-4,79%	+21,37%

11/08	Transcript : LENZ Therapeutics, Inc., Q2 2026 Earnings Call, Aug 11, 2026
11/08	LENZ Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

11/08	LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights	GL
04/08	LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026	GL
06/07	LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia	GL
24/06	LENZ Therapeutics : and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand	PU
24/06	LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand	GL
08/06	LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China	GL
26/05	LENZ Therapeutics to Participate in Upcoming Investor Conferences	GL
26/05	LENZ Therapeutics to Participate in Upcoming Investor Conferences	AQ
11/05	LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights	GL
04/05	LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference	GL
04/05	LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference	AQ
20/04	LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom	GL
24/03	LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights	GL
17/03	LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026	GL
11/03	LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ for the Treatment of Presbyopia	AQ
10/03	LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia	GL
23/02	LENZ Therapeutics to Present at Upcoming Investor Conferences	GL
15/01	LENZ Therapeutics and Sarah Jessica Parker announce the launch of Make it VIZZable, the VIZZ consumer campaign	AQ
14/01	LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign	GL
07/01	LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates	GL
06/01	LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ in the Middle East	AQ
05/01	LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East	GL
01/12	LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia	GL
25/11	LENZ Therapeutics to Present at Upcoming Investor Conferences	GL
05/11	LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights	GL